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A B S T R A C T
PLGA/PLA polymeric nanoparticles could potentially enhance the effectiveness of convective delivery of
drugs, such as carboplatin, to the brain, by enabling a more sustained dosage over a longer time than
otherwise possible. However, the link between the controlled release nanoparticle synthesis route, and
the subsequent drug release proﬁle obtained, is not well-understood, which hinders design of synthesis
routes and availability of suitable nanoparticles. In particular, despite pore structure evolution often
forming a key aspect of past theories of the physical mechanism by which a particular drug release proﬁle
is obtained, these theories have not been independently tested and validated against pore structural
information. Such validation is required for intelligent synthesis design, and NMR cryoporometry can
supply the requisite information. Unlike conventional pore characterisation techniques, NMR
cryoporometry permits the investigation of porous particles in the wet state. NMR cryoporometry
has thus enabled the detailed study of the evolving, nanoscale structure of nanoparticles during drug
release, and thus related pore structure to drug release proﬁle in a way not done previously for
nanoparticles. Nanoparticles with different types of carboplatin drug release proﬁles were compared,
including burst release, and various forms of delayed release. ESEM and TEM images of these
nanoparticles also provided supporting data showing the rapid initial evolution of some nanoparticles.
Different stages, within a complex, varying drug release proﬁle, were found to be associated with
particular types of changes in the nanostructure which could be distinguished by NMR. For a core-coat
nanoparticle formulation, the development of smaller nanopores, following an extended induction
period with no structural change, was associated with the onset of substantial drug release. This
information could be used to independently validate the rationale for a particular synthesis method.
Hence, the speciﬁc reasons for the effectiveness of the synthesis route, for obtaining core-coat
nanoparticles with delayed release, have been elucidated.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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It is well known that drug therapy can be improved by the use of
controlled release systems. Time controlled delivery is essential for
many different drugs, especially chemotherapeutics, as a spike in
the concentration of the drug can cause major side efééfects.
Further, in some instances, controlled release systems also provide
a means to increase patient compliance and convenience. They
help in maintaining the required drug concentration levels within
the body without undergoing rapid clearance. Recent studies
(Averineni et al., 2012; Avgoustakis et al., 2002; Gryparis et al.,* Corresponding author. Tel.: +44 115 951 4078.
E-mail address: enzspr@exmail.nottingham.ac.uk (S.P. Rigby).
http://dx.doi.org/10.1016/j.ijpharm.2014.04.018
0378-5173/ã 2014 The Authors. Published by Elsevier B.V. This is an open access artic2007; Hammady et al., 2009; Martinelli et al., 2011; Morgen et al.,
2012; Rescignano et al., 2012; Sant et al., 2005; Sawyer et al., 2011;
Soppimath et al., 2001; Valot et al., 2010) have revolved around the
use of biocompatible and biodegradable polymeric nanoparticles
that serve as carriers transporting drugs to the site of action. These
nanoparticles are usually synthesised by dispersing a polymer in
an organic solvent followed by transfer into a non-solvent, or by
direct polymerisation of monomers. Different synthesis routes are
available, allowing the synthesis of different kinds of nanoparticles
having unique properties, i.e., they may have a low or high drug
loading, narrow or broad size distribution, etc. These properties
result in speciﬁc drug release proﬁles following various mecha-
nisms (Lu et al., 2011; Soppimath et al., 2001; Vilar et al., 2012).
Mechanisms could include desorption of the surface bound drug,
diffusion through the polymer pore network, release controlled byle under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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diffusion and degradation. The drug release proﬁles depend on
whether or not the drug is uniformly distributed in the polymer
matrix. Generally, drug release by diffusion takes place when the
polymer matrix degrades at a far slower rate. On the other hand,
rapid initial or burst release is often attributed to the drug fraction
which is adsorbed or weakly bound to the large surface area of the
polymer nanoparticles. Thus, drug release rates of polymer
nanoparticles depend on the physical and chemical structure of
the polymer and its interaction with drug molecules (Lu et al.,
2011; Soppimath et al., 2001; Vilar et al., 2012).
The release patterns obtained depend on the nanoparticle
formulation. Time-controlled formulations allow the drug to reach
therapeutic concentrations in the tissue before gradually tailing
off. When chronic treatments are required, similar doses are
administered at regular time intervals to maintain drug concen-
trations within the therapeutic window. Unlike time-controlled
formulations, modiﬁed release formulations deliver the drug at a
deﬁned speed or site of interest. Such formulations can be
classiﬁed depending on the drug release patterns. They include
extended release formulations, sustained release formulations,
pulsatile release formulations and delayed release formulations
(Vilar et al., 2012). Table 1 features the details regarding different
formulations.
From Table 1, it can be seen that modiﬁed release formulations
provide alternatives to routine drug administration and improve
therapeutic action. They are highly beneﬁcial for drugs that show
poor bioavailability or those with a narrow therapeutic window.
They are also useful for drugs that are unstable in certain
environments or where degree of compliance is low. However,
major disadvantages of these formulations are their high produc-
tion costs, lack of reproducibility, unpredictable in vitro-in vivo
correlations and problems associated with improper handling.
Nanoparticle properties are determined with the aid of
different characterisation techniques and by studying their drug
release proﬁles. In the literature, nanoparticle characterisation is
primarily concerned with the determination of particle size, size
distribution, particle morphology and zeta (z) potential. Particle
size and size distribution are determined using dynamic light
scattering (DLS) or laser diffraction (LD). The size distribution is
usually indicated in the form of a polydispersity index. A low value
(0.1–0.25) indicates a narrow size distribution while larger values
(>0.5) refer to a broad size distribution. Particle morphology is
usually determined using different microscopy techniques, namely
scanning electron microscopy (SEM), transmission electron
microscopy (TEM) and atomic force microscopy (AFM). However,
the disadvantage of microscopy techniques are that the informa-
tion obtained is, potentially, only characteristic of the particular
section of the sample observed. They need not be representative of
the entire batch. Another property of interest is z potential which is
obtained using Laser Doppler electrophoresis. It measures theTable 1
Properties associated with different release formulations.
Formulation Properties
Extended release
formulation
Initially produce a therapeutic effect and then continue
with release which is not necessarily constant
Sustained release
formulation
Drug release with kinetic proﬁle of zero order.
Therapeutic effect is maintained over a long period of
time
Pulsatile release
formulation
Drug release in a pulsatile manner as and when
required by the body. Drug is released in accurate
amounts at the right time and place
Delayed release
formulations
Drug release does not coincide with the time of
administration. Its therapeutic action is not extended.
The presence of coatings protects the active ingredientselectrophoretic mobility of the nanoparticles suspended in a
medium and provides a measure of the stability of particles within
a medium. A z potential value >60 mV indicates excellent stability
while values <5 mV indicates quick aggregation of particles. Values
in between the above two limits usually indicate short term
stability. Other sought after properties of polymeric nanoparticles
are drug loading, drug encapsulation efﬁciency, drug release
behaviour and in vitro stability (Danhier et al., 2012; Lu et al., 2011;
Soppimath et al., 2001).
The motivation behind this paper is to determine whether drug
release patterns of polymeric nanoparticles can be related to their
pore structural evolution. Although poorly investigated, this area is
important because it will provide greater insight and understand-
ing of how nanoparticles evolve over time and what mechanism(s)
control(s) drug release. Moreover, the information obtained can
also be fed back to scientists involved in nanoparticle syntheses
allowing them to prepare nanoparticles with optimum properties,
i.e., desirable release proﬁles. Such a study therefore implies the
application of a characterisation method which explores the
evolution of the pore structure of polymeric nanoparticles. The
experiments will also help determine if pores are generated on the
outside surface or inside the particle and how they affect drug
release. It will also provide a relative comparison of the
nanoparticle pore size distributions (PSDs). The method investi-
gated in this paper is NMR cryoporometry (Mitchell et al., 2008;
Petrov and Furo, 2009; Strange et al., 1993; Webber, 2010).
To our knowledge, no previous workers have employed NMR
cryoporometry to study PLGA nanoparticles. Earlier work mainly
focussed around the use of chromatography (to determine drug
content (Averineni et al., 2012)), differential scanning calorimetry
(DSC) (to determine if the drug is well dispersed in the polymer
matrix) (Averineni et al., 2012; Sant et al., 2005), microscopy
techniques such as AFM, SEM and TEM (to determine the
morphology and size of nanoparticles) (Almeria et al., 2011;
Averineni et al., 2012; Avgoustakis et al., 2002; Gryparis et al.,
2007; Hammady et al., 2009; Rescignano et al., 2012; Sant et al.,
2005; Sawyer et al., 2011; Zhou et al., 2013; Zhu et al., 2009), DLS
(to determine particle size) (Averineni et al., 2012; Rescignano
et al., 2012; Sant et al., 2005), electrophoresis (to determine z
potential) (Averineni et al., 2012; Gryparis et al., 2007), in-vitro
and/or in-vivo drug release kinetic studies (Almeria et al., 2011;
Averineni et al., 2012; Avgoustakis et al., 2002; Hammady et al.,
2009; Sant et al., 2005; Sant et al., 2008; Sawyer et al., 2011; Zhou
et al., 2013; Zhu et al., 2009) and in-vitro cytotoxicity studies
(Averineni et al., 2012; Sawyer et al., 2011). A limited number of
studies have been conducted using pore structure characterisation
techniques on nanoparticles even though there are many studies
related to the pore structure characterisation of micron-sized
particles and mesoporous silica materials (Lee et al., 2010; Lemaire
et al., 2003; Messaritaki et al., 2005; Perkins et al., 2010; Petrov
et al., 2006; Ukmar et al., 2011; Zhu et al., 2009). Nitrogen gas
adsorption was used to study the microporosity of pegylated
nanoparticles and relate them to their drug release behaviour. The
presence and arrangement of PEG polymer chains grafted on to the
nanoparticle surface or internalised into the nanoparticle matrix
affected the microporosity of particles and thereby the drug
release kinetics (Sant et al., 2008). Earlier work by the same group
provided evidence of the change in the pore size distributions and
surface fractal dimensions depending on the formulation of the
nanoparticles (especially their drug loading and release kinetics)
(Sant et al., 2005). Another example of the application of nitrogen
gas adsorption is in the structural characterisation of templated
mesoporous materials (SBA-15 containing g-Fe2O3 nanoparticles
and a temperature responsive PNIPAM polymer) used as stimuli
responsive drug delivery agents (Zhu et al., 2009). However, it
should be noted that gas adsorption has an important limitation, in
Table 2
Different formulations and yields of nanoparticles.
Batch code Formulation Yield/%
A RG504-Nile Red-NP 7
B RG504 38 k–54 kDa 37
C 7 k–17 kDa RG502H 40
D (sourced commercially) –
E PLGA (RG504H): 2 PLA (R203H) NP 34
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may cause changes, or even damage, to the pore structure due to
the sensitivity of the polymer to humidity and high temperature.
Thus, the properties measured may not be accurate, or even reﬂect
the sample in the wetted state during use.
Thermoporosimetry using DSC has also been used to study the
pore structure of porous biopolymeric (PLGA and PLLA) nano-
particles (Rescignano et al., 2012). These DSC experiments were
supported by ﬁeld-emission SEM images which highlighted the
porous nature of nanoparticles. The Gibbs–Thomson equation (see
Eq. (3.1) in Section 3) was used to estimate the pore size within
these particles. These authors pointed out that the pore structure
could have an important implication on drug release kinetics but
did not relate structural evolution to release proﬁle. DSC has also
been used to study the drug release behaviour from albumin
nanoparticles contained within a carboxylated polyurethane
matrix (Martinelli et al., 2011). An investigation of the water
freezing and melting, water uptake and drug release kinetics was
used to purportedly determine the two main factors that
contributed to controlled drug release mechanisms. Firstly,
Martinelli et al. (Martinelli et al., 2011) reported burst release
was due to a swelling mechanism, while controlled release was
due to a diffusion dependent mechanism. They attributed the
above two mechanisms to the presence of freezing and non-
freezing fractions which aided the presence of a dual diffusion
barrier that prolonged the drug release in their materials
(Martinelli et al., 2011). However, a particular issue arises with
the use of DSC as a characterisation method. This is because it
simply measures the amount of heat released or absorbed by a
sample as the temperature is varied. This heat ﬂow need not
originate just from the liquid in the pores of the material but also
from changes in the polymer itself which cannot be independently
distinguished. In contrast, the NMR method used in this paper
monitors liquid mobility, and, if necessary, can also distinguish
between different chemical species.
Apart from the disadvantages highlighted for the two methods
previously used, earlier workers have also not related different
types of drug release characteristics to pore structural properties.
In the following sections, details will be given regarding the
synthesis of different sets of nanoparticles, their characteristic
properties, and the methodology used to determine their
respective drug release proﬁles. Details regarding the characteri-
sation method of interest, NMR cryoporometry and its theory are
also provided. In particular, the potential issue for cryoporometry,
with more realistic probe ﬂuids, of salt exclusion will be considered
to determine if it is signiﬁcant for interpreting the data for the
system studied here. Cryoporometry, using artiﬁcial cerebrospinal
ﬂuid (aCSF) as the probe ﬂuid, will be performed on a model
material. The results obtained for each of the nanoparticles will be
discussed individually. This will link pore structural evolution to
drug release experiments.
2. Materials and methods
2.1. Materials
Poly(lactide-co-glicolide) (PLGA) polymers with a 1:1 co-
polymerization ratio (ester ended RG504, MW 38 k–54 kDa, acid
ended RG504H, MW 38 k–54 kDa, and RG502H, MW 7 k–
17 kDa), poly(lactic acid) (PLA R203H, MW 18 k–24 kDa),
dichloromethane (DCM), ethyl acetate (EA) and Nile Red were
purchased from Sigma–Aldrich, UK. Polyvinyl alcohol (PVA, MW
22 kDa) was supplied by MP Biomedicals, USA. Carboplatin
solution (10 mg/ml) was obtained from Accord Healthcare Limited,
UK. aCSF was purchased from R&D systems Europe Ltd., UK. The
composition of aCSF was disodium hydrogen phosphate 19.1 g,magnesium sulphate 30 g, potassium chloride 30 g, sodium
bicarbonate 190 g, sodium chloride 730 g, hydrochloric acid qs to
between pH 7.1–7.3, and fresh distilled water to make up to 100 l.
The ionic strength of the aCSF was 0.145 mol l1. All reagents were
analytical grade or above and used as received, unless otherwise
stated. The different formulations of each batch of nanoparticles
are shown in Table 2. Also shown in Table 2 are the percentages of
ﬁnal product yields to the initial polymer input. The observed
weight loss was mainly due to the removal of the excess surfactant
and large particles pellets in the centrifuge puriﬁcation process.
Batch D was DegraFlurex PGLA (75:25) 200 nm nanoparticles
containing Carboplatin, sourced commercially from Phosphorex
Inc., Hopkinton, MA.
2.2. Nanoparticle (NP) synthesis
2.2.1. PLGA nanoparticles (samples from batches A, B, and C)
PLGA nanoparticles loaded with carboplatin were prepared
using the double-emulsion method (W1/O1/W2). 60 mg PLGA
(RG504 and RG502H) was dissolved in 2 ml DCM/EA (2:8 V/V, O1
phase) and 0.7 ml aqueous solution of carboplatin (10 mg/ml, W1
phase) was emulsiﬁed in the PLGA solution using a micro-tip probe
sonicator (Model VC 600, Sonics & materials Inc., UK), set at level 4
for 3 min. Level 4 corresponded to 20 kHz at 45 W cm2, and had
been calibrated previously (Skinner and Price, 2012). The primary
(W1/O1) emulsion was transferred into 40 ml of 2.5% PVA solution
(W2 phase) and the mixture was probe sonicated at level 4 for
5 min. The W1/O1/W2 emulsion was kept open and agitated by a
magnetic stirrer overnight at room temperature to remove the
organic solvent. In order to obtain particles with the desired
diameter, the particle solution was treated by centrifugation
(Centrifuge 5804R, Eppendorf, UK) at 9000 rpm for 15 min which
caused the large particles to form a pellet, while the smaller
particles remained in the supernatant. The pellet of large nano-
particles was removed while nanoparticles in the supernatant
were collected and washed by ultracentrifugation (40,000 rpm for
20 min, Motor type 70Ti/70.1Ti, L-80 ultracentrifuge, Beckman
Coulter, UK). This pellet of nanoparticles was re-suspended in
water, freeze-dried and stored at 253 K for further usage. To
prepare ﬂuorescent particles (batch A), the same procedure was
followed, but Nile Red was ﬁrst dissolved in DCM to form a 1 mM
solution, and 60 ml of this Nile Red solution was added to the O1
phase. Nanoparticles were synthesised with Nile Red to see if the
presence of this compound inﬂuenced the structural evolution of
the nanoparticles during incubation compared to carboplatin.
2.2.2. PLGA–PLA nanoparticles (samples from batch E)
PLGA/PLA nanoparticles were prepared by O/W emulsion
solvent evaporation techniques. PLGA (RG504H) was dissolved
in 1 ml organic solvent DCM/EA (2:8 V/V) to form ‘solution A’ while
PLA (R203H) was dissolved in 1 ml organic solvent DCM/EA
(2:8 V/V) to form ‘solution B’. Both the A and B solution
concentrations were 10% (W/V). PLGA/PLA weight ratios ranged
from 1 to 3 (W/W). 10 mg carboplatin powder was added to small
amounts of the DCM/EA solution, and sonicated using an ultrasonic
probe for 5 min to break down the drug powders into small
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and carboplatin particles were sonicated for 2 min before adding
the PLA ‘solution B’. Then the mixture of two polymeric solutions
with drug particles was sonicated for another 2 min. The resultant
solution was added drop wise into 40 ml of PVA aqueous solution
(2.5%, W/V) followed by another 5 min sonication to create an O/W
emulsion. All the sonications were performed using a micro-tip
probe sonicator (Model VC 600, Sonics & materials Inc., UK) set at
level 4. The emulsion was stirred overnight to allow the
evaporation of organic solvent and hardening of the particles.
The particles in the ﬁnal solution were puriﬁed, washed and
collected in the same process as mentioned in Section 2.2.1.
2.3. Particle size and z-potential characterisation
Freeze-dried nanoparticles were completely re-suspended in
pure water (pH 7) by agitation in an ultrasonic bath (Fisherbrand
FB 11020) for 15 min. A Zetasizer nano from Malvern Instruments
using light from a He–Ne laser source (l = 633 nm) was used for
dynamic light scattering (DLS) measurements to determine
particle size and polydispersity. All experiments were performed
at 298 K at a scattering angle of 173 to the incident beam, with an
assumed refractive index ratio of 1.59 and viscosity of 0.89 cP. The
correlation decay functions were analysed by the cumulant
method to obtain an average hydrodynamic particle size and
polydispersity. The intensity-weighted mean value presented is
the mean of three measurements. z-potential was also determined
with the Zetasizer nano ZS. By measuring the electrophoretic
mobility, the z-potential can be calculated using the Henry
equation within the Smoluchowsky approximation.
2.4. In vitro carboplatin release study
The ultimate intended use of the nanoparticles would be as
drug delivery vehicles to the brain and so artiﬁcial cerebrospinal
ﬂuid (aCSF) solution was used for the drug release studies.
Nanoparticles (5 mg) were suspended in 0.5 ml aCSF solution and
placed in a centrifuge ﬁlter tube (MWCO 10 kDa), and subse-
quently in an oven at 310 K. Samples were centrifuged at
11,000 rpm for 15 min and all aCSF solution was collected and
replaced with a fresh aliquot at predetermined intervals. Finally,
the remaining particles were then collected, dissolved in 0.6 ml
DCM and vortexed for 3 min. 1 ml aCSF was added to the solution
and the mixed solution was then vortexed for 3 min to extract
carboplatin into aCSF solution. This solution was then centrifuged
at 11,000 rpm for 15 min, and the upper aqueous solution
containing the extracted carboplatin was removed by using a
pipette and collected before fresh aCSF solution was replaced onto
the DCM solution. The whole extraction process was repeated ﬁve
times to make sure that any remaining carboplatin in the particles
was fully extracted. The carboplatin concentration in the collected
solutions was measured by Inductively Coupled Plasma Mass
Spectrometry (Thermo Fisher Scientiﬁc XSeries 2 ICP-MS) at the
Southampton Oceanography Center, UK.
2.5. NMR cryoporometry
NMR cryoporometry experiments using aCSF solution were
performed on each sample of nanoparticles. The samples were
ﬁrst immersed in aCSF solution within a pipette tip. The tip was
then sealed with paraﬁlm and introduced into an NMR tube. A
tissue wetted with aCSF solution was placed at the top of the NMR
tube and then sealed with a cap to ensure the environment was
always saturated. This sealed NMR tube was then incubated at
309.7 K. The NMR cryoporometry or freeze–melt experiments
were performed periodically using a Bruker Avance (III)spectrometer with static ﬁeld strength of 14.75 T, corresponding
to a resonance frequency of 600 MHz for 1H nuclei. Proton
intensities were obtained at different temperatures using a 1D
spin echo sequence: T-90x-180y-echo, where the echo time was
1250 ms and the relaxation delay time was 5 s. The probe used was
a ‘smart probe plus’, which was connected to a BCU II chiller
system. The ﬁrst spectrum was obtained at 278.5 K, following
which the sample was cooled to 217.8 K, since it was established
that there was no liquid-state signal at this temperature. The
system was tuned at this temperature. Thereafter, a melting cycle
was initiated using an automation program with 0.5 K increments
from 218 K to 278 K, where tuning was also carried out at each
temperature. The equilibration time at each temperature was set
at 540 s. In earlier work (Perkins et al., 2010), it was established
that this equilibration time was sufﬁciently long that the results
do not depend on equilibration time. All experiments on a
particular sample were begun and ended at identical conditions.
The spin echo spectrum at 278.5 K was used as the reference
spectrum for each run. Further, the receiver gain value was not
changed between the different runs, so the intensities were on
the same scale.
2.6. Transmission electron microscopy (TEM), environmental SEM
(ESEM) and differential scanning calorimetry (DSC)
Morphological evaluation of the nanoparticles was performed
using TEM (JEOL JEM 1200 EXII). A drop of NP suspension was
placed on a Formvar (poly(vinylformal))/carbon supported 400
mesh grid, excess liquid was removed with a ﬁlter paper, and the
grid was dried in air at room temperature followed by negative
staining with phosphotungstic acid solution (3% W/V). TEM images
were calibrated using SIRA gratings 2160 (462 nm) lines per
millimeter and catalase crystals for high magniﬁcation
(8.75/6.85 nm spacing) in the unit cell.
The morphology of the nanoparticle samples were also studied
using a PC controlled Philips XL 30 FEG ESEM. This instrument can
be used in the wet water mode or as a conventional SEM. The ESEM
images were obtained by taking a representative amount of the
nanoparticle sample and placing them on the sample holder (Batch
A) or by dispersing them in water and introducing the same to the
sample holder (Batch C). Images of Batch A were obtained by
gradually increasing the humidity from 25% to 90% and
evacuating back to 25% while batch C image was obtained in
the high vacuum mode.
A differential scanning calorimeter (Q10 DSC, TA Instruments),
equipped with a cooling unit (RCS, Refrigerated Cooling System)
for controlled cooling, was used for evaluation of glass transition
temperature. A constant furnace atmosphere was maintained with
an in-house nitrogen purge.
3. Theory
NMR cryoporometry is a technique based on the principle of
studying the melting point or freezing point depression of liquids
conﬁned in porous materials. The phase change of liquids can be
related to size of the pores in which it is conﬁned by the
Gibbs–Thomson equation:
DTm ¼ T1m  TmðxÞ ¼
4sclT
1
m
xDHfrs
cosðfÞ (3.1)
where DTm is the melting point depression; T
1
m is the normal bulk
melting point of the solid crystal; Tm(x) is the melting point of
crystals of diameter x; scl is the surface energy of the crystalline-
liquid interface; DHf is the enthalpy of fusion of the material; rs is
the density of the solid, and f is solid crystal-liquid contact angle
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to:
DTm ¼ T1m  TmðxÞ ¼
kGT
x
(3.2)
where kGT is the Gibbs–Thomson coefﬁcient. kGT can be obtained
when melting point depressions are plotted against the inverse of
the crystal size. It is a characteristic of the conﬁned liquid and sets
limit on the pore size measured. It is well known that solids, liquids
and gases have different NMR spin relaxation times. NMR
cryoporometry exploits the difference in the T2 spin relaxation
times between solids and liquids conﬁned within porous materials
such that only the signal from the liquid phase is detected. The
transition from liquid-to-solid, or solid-to-liquid, can thus be
monitored by the decay or rise in NMR signal strength,
respectively. This, along with accurate temperature control to
determine the pore size of the transition, can be used to
characterise the pore structure (Mitchell et al., 2008; Petrov and
Furo, 2009; Strange et al., 1993; Webber, 2010).
However, due to the likely inappropriateness of the bulk values,
and the difﬁculty in predicting, a priori, the values of the physical
parameters in the Gibbs–Thomson equation for highly conﬁned
geometries, the value of kGT is usually obtained by calibration of
Eq. (3.2) using a porous solid with a previously known pore size
obtained by independent means. However, there are no obvious
candidates for model polymer materials with controlled regular
pore size that could be used to calibrate the Gibbs–Thomson
equation in a fashion analogous to use of MCM-41 or SBA-15 for
silicas. Further, in this work, the key aim is to monitor the evolution
of the same void space over time and thus only relative indications
of pore size are essential. Hence, in the following discussions,
comparisons of the pore size changes over time are made in terms
of the proxy melting temperature. However, where an indicatory
pore size is of use, a typical value for kGT of 50 nm K (for oxide
materials, based on diameter) (Mitchell et al., 2008; Petrov and
Furo, 2009; Strange et al., 1993; Webber, 2010) will be employed to
obtain the pore sizes mentioned in the following text. As will be
seen below, this value is very close to that for aCSF in a silica model
material.
Artiﬁcial cerebrospinal ﬂuid contains a mixture of salts, and
thus salt exclusion effects during freezing and melting might be
important. In previous work (Perkins et al., 2010), a comparison of
freezing curves for sodium chloride soaked PLGA samples and
those in pure water showed that no salt exclusion effects were
evident. Progressive freezing of the ﬂuid within the void space
might conceivably cause salt exclusion that would be expected to
progressively generate more concentrated brine in ever smaller
molten regions that would thus have ever more depressed melting
points. Due to intra-batch/inter-sample variability in amorphous
porous media, this process might be expected to have a random
character. It has been found (Perkins et al., 2010) that, for a
nanoporous sol–gel silica material, the position of the nanopore
network melting curve was depressed by 2 K for experiments with
5% W/V sodium chloride solution compared to analogous experi-
ments with pure water. However, within experimental error, the
curves could be superposed once the temperatures for data-points
in the water curve had all been reduced by 2 K. Since, if occurring,
the aforementioned salt exclusion effects might be expected to
broaden the distribution of freezing and melting temperatures,
compared to that for pure water, this ﬁnding suggested that salt
exclusion effects on the shape of the distribution were negligible.
Previous work (Perkins et al., 2010) has considered salt exclusion
using 5% W/V sodium chloride solution as the probe ﬂuid. Since the
experiments on PLGA were run over an extended period of time
(Perkins et al., 2010), effects arising from the progressive
concentration, or dilution, of the (bulk and pore) salt solutiondue to liquid evaporation, or interaction of the salt with the
polymer, respectively, might be anticipated. However, no system-
atic change in the melting point for the bulk solution with time was
seen in the experiments, and thus the effects of evaporation (from
the sealed container) and long-term salt–polymer interaction were
considered negligible. The lack of change of bulk melting point
indicates no signiﬁcant salt–polymer interaction for the following
reasons. If there is a salt–polymer interaction then the ions are
likely to adsorb on the polymer, which being micro-/nano-
particulate and having nanopores will have a large surface area
for this to occur, if it were to do so to a large extent. This would
mean that the bulk liquid surrounding the nanoparticles would be
depleted of ions, and thus the effect of the ions on the bulk melting
point would be reduced, and it would be expected that the bulk
melting point would be less depressed. This effect is not seen and
thus there cannot be any signiﬁcant ion-polymer interaction. It has
also been checked that the frequency of cryoporometry experi-
ments used does not, itself, alter the trajectory of the pore structure
evolution in PLGA samples.
4. Results
4.1. Cryoporometry of model silica material
The model material used was a sol–gel silica sphere, denoted G1,
which has been fully described and characterised using gas sorption
and mercury porosimetry previously (Perkins et al., 2010). The pore
size distribution obtained from a calibrated version of the Washburn
equation was found to have a modal pore size of 10 nm.
Cryoporometry melting curves were obtained for G1 using either
aCSF or pure water as the probe ﬂuid, and the results for both are
shown in Fig. 1(a). Also included in Fig. 1(a) is the melting curve for
bulk aCSF alone. For samples with G1, the small step at high
temperature (273 K) is attributed to the melting of the ﬁlm of bulk
liquid surrounding the pellets, while the larger step at lower
temperature is attributed to melting of intra-particle ﬂuid. From
Fig.1(a), it can be seen that melting within G1 is depressed below the
bulk melting point for water of 273.15 K. The melting point
depression of aCSF within G1 is 5 K, which, in conjunction with
the knownmodalpore size for G1, suggestsavalueofkGTof 50 nm K is
probably reasonably appropriate for aCSF. It is also noted that the
form of the melting curve for aCSF within G1 is very similar to that
for pure water, though just shifted slightly lower in temperature.
However, the melting curve step for aCSF within G1 is much sharper
than the melting curve step for bulk aCSF. At the lowest temper-
atures (below 247 K) the melting curve for bulk aCSF is relatively ﬂat
with little signal, but at about 250–251 K there is a pronounced
step up in intensity, followed by a long slow climb in intensity with
increasing temperature, before increasing much more sharply in
intensityabove 270 K. The melting curve for aCSF within G1 does not
have this same long tail, or the same pronounced step at
250–251 K. The 250–251 K step for the bulk aCSF sample is
attributed to the melting of the pocket of high salt concentration
solution produced by salt exclusion. The very slight bump in the
curve for aCSF and G1 at the same temperature may be due to the
same salt exclusion effect within the small amount of bulk aCSF
present outside the pellets themselves, the presence of which is
indicated by the small step at 273 K for the pellet samples. In
Fig. 1(b) it can be seen that the superposed differential pore size
distributions derived from the cryoporometry melting curves for
water and aCSF, respectively, within G1 are very similar in form.
4.2. Nanoparticle properties
The characteristic properties of the different nanoparticulate
formulations are given in Table 3. The particle size for the different
Fig.1. (a) NMR cryoporometry melting curve data for bulk aCSF solution, and for aCSF imbibed in silica G1, and also for pure water in G1. The inset shows the same data curves
at low temperatures. (b) Differential pore size distributions derived from melting curves for pure water and aCSF imbibed in samples from batch G1.
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sample, was found to have the smallest particle size, while batch E
had the largest particle size. The polydispersity for all batches was
less than 0.2 indicating a narrow size distribution. The zeta
potential of PLGA nanoparticles can be affected by the polymer end
group. In Table 3, the zeta potential is 23 mV for the ester-
terminated, and 33 mV for the COOH-terminated, PLGA-NPs,
which is close to values previously reported by Ghotbi et al. (Ghotbi
et al., 2011). The zeta potential for pure PLGA nanoparticles
prepared without any PVA in a neutral environment is about
45 mV. This high negative charge is due to the presence of
uncapped end carboxyl groups of the polymer at the particleTable 3
Different formulations of nanoparticles and their characteristic properties.
Batch Particle
diameter
(nm)
Polydispersity z-potential
(mv)
Carboplatin drug
loading/wt%
A 190.7  1.7 0.089  0.013 28.8  0.5 –
B 182.8  3.9 0.092  0.019 22.9  0.9 0.30
C 167.7  0.3 0.093  0.021 32.8  1.0 0.17
Da 146.2  1.5 0.115  0.032 25.2  0.5 0.0072
E 193.5  0.9 0.097  0.010 26.5  0.4 1.3
a Batch D was obtained from a commercial company. The preparation procedure
was not known.surface. In our study, the nanoparticles were all prepared with the
emulsiﬁer polyvinyl alcohol (PVA), a fraction of PVA remains
associated with the nanoparticle, despite repeated washing, since
PVA forms an interconnected network with the polymer at the
interface. The PVA layer at the nanoparticle surface probably
shields the PLGA surface charge; and particles with less shielding
should be expected to have larger absolute zeta potential value.
According to Sahoo et al. (Sahoo et al., 2002), the PVA residual in
our nanoparticles should be less than 0.5%. DSC data (not shown)
was also obtained for the nanoparticles, with a ramp rate of
10 K min1 from 193 to 523 K. In addition to a sharp water peak at
373 K, the glass transition was also observed, which occurred at
316 K for batch A, for example, which is the same as that observed
for similar PLGA particles (Passerini and Craig, 2001).
4.3. Batch A – ESEM and NMR cryoporometry with aCSF
Batches A and B were identical except that batch A contained
Nile Red, while batch B contained carboplatin. The pore structural
evolution of nanoparticles from batch A following exposure to
water vapour, or immersion in aCSF solution, was studied using
microscopy techniques or NMR cryoporometry respectively. These
two methods enabled the study the nanoparticle structure over
both very short and long evolutionary time scales, i.e. of the order
Fig. 2. ESEM (a and b) images of aggregates of polymer nanoparticles, from batch A. Images (a) and (b) were obtained after exposing the sample to 100% RH for 124 and
128 min respectively. The time quoted is the cumulative exposure time. Image (a) shows the suspension of nanoparticles, and Image (b) shows the gel into which the
aggregates changes.
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increasing levels of relative humidity (RH), from 5% to 100%, to
study the interaction of the sample with water vapour. At 100%
RH, a gel or paste formation was observed. Water vapour
condensed in particular isolated regions of the sample, and then
began ﬂooding the sample, leading to the formation of a
suspension, as seen in Fig. 2(a). Fig. 2(a) was obtained after
exposing the same to water vapour for 2 h. A few minutes later, a
thick gel had formed, as seen in Fig. 2(b). Upon drying the sample
to 48% RH and then to 21% RH, the paste remained visible.
The ESEM images provided a qualitative understanding of the
interaction between water vapour and the nanoparticle aggregate
structure during short time intervals. However, the NMR
cryoporometry technique was used to study the evolution of the
particle nanoscale structure, following immersion in aCSF, over
longer time intervals. Evolution of the nanoparticle structure
would be evident from any visible shifts in the melting proﬁle of
the probe ﬂuid. As longer time scales were of interest, the melting
proﬁles of aCSF solution containing nanoparticles belonging to
batch A were obtained periodically after 1, 2 and 3 day(s) of
incubation at 309.7 K. Fig. 3 presents the melting proﬁles of aCSF
solution containing nanoparticles of batch A. The melting curves0 
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Fig. 3. NMR cryoporometry data for polymer nanoparticles from batch A immersed in
obtained after 1 day, 2 days and 3 days of incubation.obtained after 1 day, 2 days, and 3 days of incubation showed
no signiﬁcant difference from each other.
4.4. Batch B – TEM and NMR cryoporometry with aCSF
NMR cryoporometry was used to study the pore structural
evolution of polymer nanoparticles from batch B immersed in
aCSF. Fig. 4 presents the melting proﬁle of aCSF solution containing
the nanoparticles from batch B. The melting proﬁles were obtained
after 1 and 2 days of incubation. Fig. 4 also shows the
carboplatin drug release proﬁle for these nanoparticles. The
individual symbols situated at various points along the release
proﬁle correspond to the times at which the melting proﬁles
(displayed with same symbol shape) were obtained. It was found
that 98.9% of the drug was released in 24 h and over the next 48 h
there was only a 1% increase in the drug released. The melting
proﬁles of the solution containing nanoparticles after 1 and 2
days of incubation were found to be very similar showing very little
increase in pore volume over the period investigated. The data
obtained after 2 days, shown in Fig. 4, are located above the data
obtained after 1 day of incubation. It was also noted that the step
present in the melting curve for the bulk solution at a temperature255  260  265  270 
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Fig. 4. NMR cryoporometry data (chains of symbols) for polymer nanoparticles belonging to batch B immersed in aCSF. The melting proﬁles of the aCSF solution containing
the nanoparticles were obtained after 1 day, and 2 days of incubation. The percentage carboplatin released from the nanoparticles of batch B has been plotted (with line
shown to guide the eye) against time on the secondary axes, with melting curves taken at the times indicated by the relevant symbol.
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nanoparticles (similar to batch A seen previously). Instead the
melting proﬁle was smooth and broad over the entire temperature
range.
It is also noted that the melting proﬁles obtained for batches A
and B are very similar in shape over the time intervals studied.
Fig. 5(a) shows a TEM image of nanoparticles from batch B. It can be
seen that they have a round morphology.Fig. 5. (a) TEM images of nanoparticles from batch B negatively stained with phosphotun
were obtained after preparing a suspension of nanoparticles in water. The images show4.5. Batch C – ESEM, TEM and NMR cryoporometry with aCSF
Batch C was studied using ESEM, TEM and NMR cryoporometry.
The ESEM and TEM images were obtained after dispersing the
sample inwaterand thenplacingthem on a grid.Theyclearlyshowed
the presence of spherical nanoparticles, as seen in Fig. 5(b and c).
These nanoparticles are of the order of 100 nm in size. The melting
curves of aCSF solution containing nanoparticles from batch C, andgstic acid. ESEM (b) and TEM (c) of polymer nanoparticles from batch C. The images
 the size and morphology of the nanoparticles.
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Fig. 6. NMR cryoporometry data (symbols) for polymer nanoparticles from batch C immersed in aCSF. The melting proﬁles of the aCSF solution containing the nanoparticles
were obtained after 18 h and 2 days of incubation. The percentage carboplatin released from the nanoparticles has been plotted (with line shown to guide the eye) against
time on the secondary axes. The lone symbols also located along the line, matching those from the melting curves, indicate when those melting proﬁles were obtained.
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release proﬁle shows a pulse release of 90% of the drug within the
ﬁrst half-day, and thereafter a long slight tail. The melting curves of
the aCSF solution containing nanoparticles from batch C were
obtained after 18 h and 2 days. As seen earlier for batch A and
batch B, the melting curves were similar after 18 h and 2 days.
However, unlike the smooth melting curves obtained for samples
from batches B and A, the melting curves of sample C had the
presence of a steeper melting step. The time points at which each
melting proﬁle was obtained can be seen in the drug release proﬁle,0 1 2 3 4 5 
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Fig. 7. NMR cryoporometry data (symbols) for bulk aCSF solution, and for polymer nano
days and 9 days. The percentage carboplatin released has been plotted (line) againstindicated by each lone symbol corresponding to the appropriate
melting proﬁle. As evident from the drug release data, there is very
little change in shape of the drug release proﬁle during the time
interval investigated. This also correlated with the little change in
melting proﬁles of the aCSF solution in the same time period.
4.6. Batch D – NMR cryoporometry with aCSF
The melting curves of aCSF solution containing nanoparticles
from batch D, and their drug release proﬁle are plotted in Fig. 7. It0 
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ous or burst release of 60% of its drug content within the ﬁrst 12 h.
After this initial burst release (within half a day), the remaining
40% of the drug was gradually released over 10.5 days. A
declining release rate was noted in the drug release proﬁle tail at
later times, unlike the burst release samples seen earlier. The
cryoporometry melting curves were obtained after 2 h, 2 days
and 9 days of incubation. A roughly three times increase in the
volume of small to medium sized (2–4 nm, corresponding to
248–260 K) pores was evident in the melting curves when
comparing the results obtained following 2 h of incubation, and
following 2 days of incubation. This time period corresponded to
a signiﬁcant jump in the amount of drug released from the
nanoparticles (62% drug released). At later times, it was found
that there was little change in the melting proﬁle which
corresponded to the lesser amount of drug released over that
period (16% drug released).
4.7. Batch E – ESEM and NMR cryoporometry with aCSF
Batch E comprised spherical nanoparticles (Fig. 8) that were
100 nm in size. As can be seen from the drug release proﬁle given
in Fig. 9, it was observed that nanoparticles from batch E provided a
very small initial burst, and then very little drug release during the
next 24 h. Thereafter there was a period of signiﬁcant sustained
drug release lasting 2 days, before the release ﬁnally tailed off and
reached a plateau. From a consideration of the cryoporometry
melting curves for nanoparticles from batch E (Fig. 9), it was found
that that the melting curves remained very similar over the period
of 2.5 h to 1 day, with, maybe, a very slight rise in nanopore
volume. However, between 1 day and 2 days, when there was a
signiﬁcant change in amount of drug released (24%), there was
also a signiﬁcant shift in the melting curve (Fig. 9). The shapes of
the melting curves suggest that the volume of pores of sizesFig. 8. ESEM images of spherical polymer nanoparticles from batch E in the native stat
negatively stained with phosphotungstic acid. The images show the size and morpholo1–2 nm (corresponding to 230–248 K) increased by about ﬁve
times between 1 and 2 days. Following this period of change, the
melting curves obtained over 2, 3 and 4 days were very
similar. The drug release proﬁle after 24 h was ﬁtted to an
exponential growth phenomenological mathematical model. The
model ﬁtted the data reasonably well (the coefﬁcient of
determination of the ﬁt was 0.972) and the time constant for
the function was 0.05 h1.
5. Discussion
The absence of a pronounced, low temperature (250–251 K)
step, similar to that observed for bulk aCSF, in the cryoporometry
data (see Fig. 1(a)) for melting of aCSF within the model silica
material suggested that a similar salt exclusion effect was not
occurring within the porous material as occurred for the bulk-only
sample. This is further conﬁrmed by the ﬁnding that the forms of
the intra-particle melting curve, and pore size distribution derived
from it, for aCSF in G1 are very similar to the corresponding results
for pure water in G1 (Fig.1(b)). If salt exclusion affected the melting
of aCSF imbibed in G1, as observed for the bulk aCSF sample, then
the data for aCSF in G1 would be expected to be asymmetric with a
long tail to low temperature (small pores). Hence, it was concluded
that salt exclusion effects were not important for interpreting
cryoporometry melting curves for aCSF in mesoporous solids.
It was found that the ﬁve different batches of nanoparticles
studied here gave rise, between them, to three different forms of
drug release proﬁles. The reasons for the different forms of the
drug release proﬁles can be deduced from the complementary data
obtained from NMR and EM. Both the experimental methods
provided useful information on the interaction between water or
aCSF solution and the nanoparticle structure. The structural
evolution of nanoparticles allows water to penetrate the structure,
which can be detected by NMR. The melting point of that water, ine. (b) is a zoomed out version of (a). (c) TEM image of nanoparticles from batch E
gy of the nanoparticles.
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Fig. 9. NMR cryoporometry data (chains of symbols) for polymer nanoparticles from batch E immersed in aCSF. The melting proﬁles of the aCSF solution containing the
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or absence, of these pores, and the ability of water to penetrate the
structure, or not, depends on how the structure of the nano-
particles evolves.
Evidence for the presence of a correlation between the
evolution of the nanoparticle pore structure and the drug release
characteristics was established. Importantly, the microscopy
technique provided an understanding of how water vapour
interacted with the nanoparticle aggregate structure over short
time scales (minutes or hours), while the NMR cryoporometry
technique revealed nanoparticle pore structural information over
longer time scales. The time scales investigated varied from a few
hours to a few days. Where the NMR data for a particular batch
exhibited a signiﬁcant increase in 1H NMR intensities over a
particular range of temperatures, such a shift was attributed to the
development, and evolution, of pores. The different batches were
chosen as they exhibited different release characteristics, i.e., burst
(A, B, C), controlled (D, E) and delayed (D, E) release characteristics.
The steep melting step in the melting curve data for the bulk
aCSF (see Fig.1, 250–251 K) is probably due to salt exclusion effects,
whereby the salts in the aCSF are steadily excluded into remaining
liquid until the ﬁnal highly concentrated salt solution ﬁnally
solidiﬁes, and, thence, also melts at low temperature compared to
bulk. However, the shapes of the melting curves for aCSF imbibed
within nanoparticle samples were very different to that for bulk
aCSF, and this ﬁnding, together with those from aforementioned
studies (Perkins et al., 2010) of potential salt exclusion effects for
solutions imbibed within nanoporous media, suggest that salt
exclusion does not contribute signiﬁcantly to the results for the
nanoparticle samples studied here.
The cryoporometry melting curves for aCSF imbibed within
nanoparticles from batches A, B, and C all exhibited very little
change over the time-scales measured. The absence of any shift in
the aCSF solution melting temperatures for batches A, B and C
indicated the absence of any pore structural change over the same
time scales. The marked step in the melting curves for batch C
around 250 K, that is not present in the melting curves for batches
A and B, suggests a network of pores with a relatively narrow rangeof sizes, and could arise for a reason related to the fact that batch C
is composed of polymer of lower molecular weight than batches A
and B. In all of these batches, the vast majority of the drug (090%)
had already been released in the ﬁrst few hours of incubation. Such
a burst release of the drug could possibly be due to the washing
away of the drug from the surface of the nanoparticle itself. Thus, a
relation was found to exist between the drug release proﬁle and
the melting proﬁles of batches A and B obtained at different times.
Little change or shift in the melting proﬁles of the aCSF solution
agreed with the little change in the drug amounts released.
Furthermore, microscopy studies showed a rapid gel or paste
formation upon exposure to 100% RH in batch A demonstrating
the rapid response of the nanoparticle aggregate to moisture,
which would facilitate the burst release of a drug. The slightly
lower initial burst release for batch C (90% of drug), relative to
batch B (95–99%), may be because the acid end group of the
polymer used to make batch C may have had a slightly greater
afﬁnity for the drug, leading to a smaller initial burst release. The
remaining 10% of the drug in batch C may be retained by the end
group and thus slowly released over 0.5–9 days.
Unlike batches B and C, which showed predominantly burst
release characteristics, batch D had an initial period that exhibited
partial burst release of up to 60% of the drug, but this was then
followed by a second period that showed substantial delayed release
in a long tail. The aCSF solution melting curve obtained after 2 days
of incubation showed greater 1H NMR intensity relative to that
obtained earlier, after only 2 h of incubation. This indicated
swelling and pore volume generation within the nanoparticle
structure had occurred between the initial pulse release period, and
the onset of the delayed tail. It is noted that this change took place
over a time period when 60% of the drug content was released. The
remaining drug content was released in a delayed manner with very
little evolution in the pore structure. The absence of both any
structural change and any substantial delayed release period for
batches B and C, but the association, observed for batch D, between
the period of the changeover from pulse to delayed release with a
concomitant structural change, suggests that the mechanisms of
drug release for these two periods are different, with the delayed
N. Gopinathan et al. / International Journal of Pharmaceutics 469 (2014) 146–158 157release being associated with a more open pore structure. It can thus
be inferred that release in the second period is controlled by the
migration of drug through the evolving pore structure.
The behaviour of Batch E was distinctly different again from
that of the other nanoparticles. It was characterised by an initial
time period within which there was very little change in the
nanoparticle pore structure and very little drug release. This time
period was nearly 24 h. Thereafter, the drug amount released
increased by a substantial amount, and that release occurred in a
controlled, or sustained, manner over the following two days. It
was only during the early part of this second period that
the nanoparticle pore structure evolved substantially, as evidenced
by the NMR cryoporometry data. This second period was
characterised by the generation of accessible nanoporous void
volume 4–5 times larger than previously present. Most of the
pores were in the small size range (1–2 nm). At later stages, when
the amount of drug released approached 90%, there was very little
change in the form of the melting curve from that obtained after 3
days of incubation. Hence, the observed evolution of the pore
structure is mostly conﬁned to the period 1–2 days, associated
with the onset of sustained release. Thereafter, the structure
generally stays open allowing the drug to diffuse easily out. The
synthesis of batch E was similar to the polymer-alloys method used
to synthesise double-walled PLA–PLGA microspheres (Lee et al.,
2002; Matsumoto et al., 1997). The form of the drug release proﬁle
for batch E, with a delay followed by a steady release, was similar to
that observed for double-walled microspheres (Lee et al., 2002). In
the solvent evaporation process during the synthesis of these
materials the polymer total weight increases above 30% so a phase
separation is achieved. Small spheres of the more hydrophilic and
faster degrading PLGA become entrapped within a stronger PLA
coating (Lee et al., 2002). Cisplatin tends to associate with the PLGA
phase (Matsumoto et al., 2005), and it might be expected that
carboplatin would behave similarly. A mechanism has been
proposed for the release of drug from multi-reservoir, double-
walled microspheres (Matsumoto et al., 2005). Initially, only drug
bound loosely to the exterior of the microsphere is released.
Subsequently, erosion of the outer PLA coating occurs, forming a
few micropores. Thereafter, erosion of the PLGA core occurs and
the drug is released. Finally, more effective pores in the drug-free
PLA layer are generated. The small size of the nanoparticles meant
that the same microscopy methods used to study microparticles
(Lee et al., 2002; Matsumoto et al., 1997; Matsumoto et al., 2005)
could not feasibly be used for the nanoparticles. However,
cryoporometry offers another means by which particle structural
evolution can be monitored at the nanoscale. The cryoporometry
results have shown that drug release from batch E nanoparticles is
generally consistent with the aforementioned mechanism for
microparticles (Matsumoto et al., 2005). Upon initial immersion in
aCSF, a very small amount of drug is released from the exterior
surface of the nanoparticles. There is then an induction period of
1 day and the slight rise in the melting curve over this period (in
Fig. 9) might be associated with the erosion of some micropores in
the outer PLA coating of the nanoparticles. The sudden release of
drug and substantial increase in pore volume in the melting curve
may be associated with the ﬁnal penetration of the micropores in
the PLA through to the PLGA core which is more rapidly degraded.
The exponential growth form of the drug release proﬁle, once
breakthrough of the microporous passages to the core has been
achieved, means that the rate of drug release declines with
remaining drug concentration, which would be consistent with a
diffusional mechanism, whereby the drug has to diffuse from the
core through the now permeable outer barrier layer.
Hence, it has been shown that the forms of the NMR
cryoporometry melting curves presented in this paper correlated
strongly with forms of the drug release proﬁle data. The workshowed that drug release experiments alone cannot provide an
understanding of the pore structural evolution of polymeric
nanoparticles. It is only by comparison with a pore structural
characterisation technique that a mechanistic understanding can
be achieved. In contrast to our approach and ﬁndings, Martinelli
et al. (Martinelli et al., 2011) have used DSC and drug release
experiments to determine that the burst release effect is correlated
with the presence of a larger freezing fraction when the sample is
frozen, and arises due to swelling. On the other hand, controlled
release was correlated by them with the presence of a higher non-
freezing fraction during thermoporometry. A reason for the
difference with our ﬁndings described here could be due to the
different polymers involved in the respective studies.
6. Conclusion
This work has directly demonstrated that different synthesis
routes for nanoparticles leads to different pathways in the evolution
of the pore structure which gives rise to the different observed drug
release proﬁles. This work has elucidated this previously unclear link
between synthesis method and release proﬁle. This has enabled
theoretical proposals for the speciﬁc mechanism(s) of drug release
for nanoparticles synthesised in a particular way to be tested and
validated. In particular, the rationale for the design of the synthesis
route for a core-coat structured nanoparticle, and the proposed
mechanism for delayed drug release in such particles, have been
independently validated.Hence, the cryoporometry methodpermits
a more intelligent design of nanoparticle synthesis to achieve a
particular release proﬁle.
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